This Non-Cystic Fibrosis Bronchiectasis market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The non-cystic fibrosis bronchiectasis market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.74 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising incidence and prevalence, advances in diagnostic technologies, growing geriatric population, government support and funding, improved healthcare infrastructure, increased diagnosis awareness, rising geriatric population, environmental exposure.
The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advances in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, growing research and development, public health initiatives, the global aging population, and the development of targeted therapies. Major trends in the forecast period include digital health solutions, a focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the growth of mobile health (mHealth) solutions.
The non-cystic fibrosis bronchiectasis market is poised for growth due to the increasing incidence of respiratory diseases. These diseases encompass various conditions affecting lung and respiratory function, exacerbated by rising environmental pollution, both outdoors and indoors, such as tobacco smoke. The uptick in respiratory infections presents opportunities for advancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health initiatives. Recent data from a June 2023 report by the UK's Office for Health Improvement and Disparities highlighted a significant rise in scarlet fever Group A Streptococcus bacteria notifications during the 2022-2023 season in England, underscoring the escalating trend in respiratory illnesses. This trend underscores the anticipated growth in the non-cystic fibrosis bronchiectasis market.
Leading companies in the non-cystic fibrosis bronchiectasis market are increasingly adopting personalized medicine strategies, particularly through innovations such as nebulization solutions, to enhance the efficiency of drug delivery and improve patient adherence. Nebulization technologies represent a cutting-edge approach for precise administration of respiratory medications, thereby boosting treatment adherence and overall therapeutic outcomes. For example, in April 2022, Zambon S.P.A., a prominent pharmaceutical firm based in Italy, secured a designation from the US FDA for CMS I-neb therapy aimed at patients suffering from non-cystic fibrosis bronchiectasis (NCFB). This therapy is investigational and potentially revolutionary as an inhaled treatment for adult NCFB patients infected with P. aeruginosa, a significant milestone in advancing treatment options for this chronic and progressive respiratory condition. The breakthrough designation underscores the accelerated development and regulatory review pathway for CMS I-neb in NCFB.
In November 2023, Chiesi Farmaceutici SpA, an Italian pharmaceutical company, announced a partnership with Haisco Pharmaceutical Group Co., Ltd. This collaboration focuses on Haisco's commercialization of Chiesi's investigational bronchiectasis drug in China. Haisco will provide financial and logistical support to facilitate regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis treatment to the Chinese market. Haisco Pharmaceutical Group Co. Ltd., based in China, specializes in developing treatments for respiratory diseases, including bronchiectasis.
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc.
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-cystic fibrosis bronchiectasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Non-cystic fibrosis bronchiectasis is a persistent condition marked by permanent widening and abnormality of the airways (bronchi) in the lungs. This results from recurrent inflammation and infections, which weaken and damage the walls of the bronchial tubes. Symptoms include mucus buildup, chronic coughing, breathlessness, and frequent respiratory infections. Treatment typically focuses on symptom management, preventing flare-ups, and addressing underlying factors such as bacterial infections or immune system dysfunction.
Diagnosis of non-cystic fibrosis bronchiectasis involves various methods including computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function tests, sputum culture, and blood tests. CT scans provide detailed lung images that help in diagnosing bronchiectasis by revealing the extent and location of lung damage. Treatment options are categorized into surgical interventions, physiotherapy, vaccinations, airway pharmacotherapy, antibiotics, and others. These treatments are utilized across different healthcare settings such as hospitals, clinics, and ambulatory care centers.
The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports that provides non-cystic fibrosis bronchiectasis market statistics, including non-cystic fibrosis bronchiectasis industry global market size, regional shares, competitors with an non-cystic fibrosis bronchiectasis market share, detailed non-cystic fibrosis bronchiectasis market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. This non-cystic fibrosis bronchiectasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The non-cystic fibrosis bronchiectasis market size has grown strongly in recent years. It will grow from $3.5 billion in 2024 to $3.74 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to rising incidence and prevalence, advances in diagnostic technologies, growing geriatric population, government support and funding, improved healthcare infrastructure, increased diagnosis awareness, rising geriatric population, environmental exposure.
The non-cystic fibrosis bronchiectasis market size is expected to see strong growth in the next few years. It will grow to $4.82 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to advances in personalized medicine, the emergence of new biomarkers, increased investment in respiratory medicine, growing research and development, public health initiatives, the global aging population, and the development of targeted therapies. Major trends in the forecast period include digital health solutions, a focus on targeted therapies, the integration of AI and machine learning, a shift towards home-based care, patient-centric approaches, and the growth of mobile health (mHealth) solutions.
The non-cystic fibrosis bronchiectasis market is poised for growth due to the increasing incidence of respiratory diseases. These diseases encompass various conditions affecting lung and respiratory function, exacerbated by rising environmental pollution, both outdoors and indoors, such as tobacco smoke. The uptick in respiratory infections presents opportunities for advancing the understanding, diagnosis, and management of non-cystic fibrosis bronchiectasis through targeted interventions and public health initiatives. Recent data from a June 2023 report by the UK's Office for Health Improvement and Disparities highlighted a significant rise in scarlet fever Group A Streptococcus bacteria notifications during the 2022-2023 season in England, underscoring the escalating trend in respiratory illnesses. This trend underscores the anticipated growth in the non-cystic fibrosis bronchiectasis market.
Leading companies in the non-cystic fibrosis bronchiectasis market are increasingly adopting personalized medicine strategies, particularly through innovations such as nebulization solutions, to enhance the efficiency of drug delivery and improve patient adherence. Nebulization technologies represent a cutting-edge approach for precise administration of respiratory medications, thereby boosting treatment adherence and overall therapeutic outcomes. For example, in April 2022, Zambon S.P.A., a prominent pharmaceutical firm based in Italy, secured a designation from the US FDA for CMS I-neb therapy aimed at patients suffering from non-cystic fibrosis bronchiectasis (NCFB). This therapy is investigational and potentially revolutionary as an inhaled treatment for adult NCFB patients infected with P. aeruginosa, a significant milestone in advancing treatment options for this chronic and progressive respiratory condition. The breakthrough designation underscores the accelerated development and regulatory review pathway for CMS I-neb in NCFB.
In November 2023, Chiesi Farmaceutici SpA, an Italian pharmaceutical company, announced a partnership with Haisco Pharmaceutical Group Co., Ltd. This collaboration focuses on Haisco's commercialization of Chiesi's investigational bronchiectasis drug in China. Haisco will provide financial and logistical support to facilitate regulatory approval, marketing, and distribution efforts necessary for introducing the bronchiectasis treatment to the Chinese market. Haisco Pharmaceutical Group Co. Ltd., based in China, specializes in developing treatments for respiratory diseases, including bronchiectasis.
Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc, Teva Pharmaceutical Industries Ltd, Vertex Pharmaceuticals, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr Reddy's Laboratories Ltd, Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc, Insmed Incorporated, Genentech, Zydus Cadila, Santhera Pharmaceuticals, TSRL Inc.
North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2024. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-cystic fibrosis bronchiectasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Non-cystic fibrosis bronchiectasis is a persistent condition marked by permanent widening and abnormality of the airways (bronchi) in the lungs. This results from recurrent inflammation and infections, which weaken and damage the walls of the bronchial tubes. Symptoms include mucus buildup, chronic coughing, breathlessness, and frequent respiratory infections. Treatment typically focuses on symptom management, preventing flare-ups, and addressing underlying factors such as bacterial infections or immune system dysfunction.
Diagnosis of non-cystic fibrosis bronchiectasis involves various methods including computed tomography (CT) scans, bronchoscopies, chest X-rays, lung function tests, sputum culture, and blood tests. CT scans provide detailed lung images that help in diagnosing bronchiectasis by revealing the extent and location of lung damage. Treatment options are categorized into surgical interventions, physiotherapy, vaccinations, airway pharmacotherapy, antibiotics, and others. These treatments are utilized across different healthcare settings such as hospitals, clinics, and ambulatory care centers.
The non-cystic fibrosis bronchiectasis market research report is one of a series of new reports that provides non-cystic fibrosis bronchiectasis market statistics, including non-cystic fibrosis bronchiectasis industry global market size, regional shares, competitors with an non-cystic fibrosis bronchiectasis market share, detailed non-cystic fibrosis bronchiectasis market segments, market trends and opportunities, and any further data you may need to thrive in the non-cystic fibrosis bronchiectasis industry. This non-cystic fibrosis bronchiectasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The non-cystic fibrosis bronchiectasis market consists of revenues earned by entities by providing services such as diagnostic imaging, pulmonary function testing, medical consultations, home healthcare, pulmonary rehabilitation, and management of chronic respiratory infections through pharmaceutical treatments and advanced therapeutic technologies. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-cystic fibrosis bronchiectasis market also includes sales of antibiotics, bronchodilators, mucolytics, inhalers, nebulizers, airway clearance devices, and respiratory monitoring devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Non-Cystic Fibrosis Bronchiectasis Market Characteristics3. Non-Cystic Fibrosis Bronchiectasis Market Trends and Strategies4. Non-Cystic Fibrosis Bronchiectasis Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Non-Cystic Fibrosis Bronchiectasis Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Non-Cystic Fibrosis Bronchiectasis Market34. Recent Developments in the Non-Cystic Fibrosis Bronchiectasis Market
5. Global Non-Cystic Fibrosis Bronchiectasis Growth Analysis and Strategic Analysis Framework
6. Non-Cystic Fibrosis Bronchiectasis Market Segmentation
7. Non-Cystic Fibrosis Bronchiectasis Market Regional and Country Analysis
8. Asia-Pacific Non-Cystic Fibrosis Bronchiectasis Market
9. China Non-Cystic Fibrosis Bronchiectasis Market
10. India Non-Cystic Fibrosis Bronchiectasis Market
11. Japan Non-Cystic Fibrosis Bronchiectasis Market
12. Australia Non-Cystic Fibrosis Bronchiectasis Market
13. Indonesia Non-Cystic Fibrosis Bronchiectasis Market
14. South Korea Non-Cystic Fibrosis Bronchiectasis Market
15. Western Europe Non-Cystic Fibrosis Bronchiectasis Market
16. UK Non-Cystic Fibrosis Bronchiectasis Market
17. Germany Non-Cystic Fibrosis Bronchiectasis Market
18. France Non-Cystic Fibrosis Bronchiectasis Market
19. Italy Non-Cystic Fibrosis Bronchiectasis Market
20. Spain Non-Cystic Fibrosis Bronchiectasis Market
21. Eastern Europe Non-Cystic Fibrosis Bronchiectasis Market
22. Russia Non-Cystic Fibrosis Bronchiectasis Market
23. North America Non-Cystic Fibrosis Bronchiectasis Market
24. USA Non-Cystic Fibrosis Bronchiectasis Market
25. Canada Non-Cystic Fibrosis Bronchiectasis Market
26. South America Non-Cystic Fibrosis Bronchiectasis Market
27. Brazil Non-Cystic Fibrosis Bronchiectasis Market
28. Middle East Non-Cystic Fibrosis Bronchiectasis Market
29. Africa Non-Cystic Fibrosis Bronchiectasis Market
30. Non-Cystic Fibrosis Bronchiectasis Market Competitive Landscape and Company Profiles
31. Non-Cystic Fibrosis Bronchiectasis Market Other Major and Innovative Companies
35. Non-Cystic Fibrosis Bronchiectasis Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Non-Cystic Fibrosis Bronchiectasis Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on non-cystic fibrosis bronchiectasis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for non-cystic fibrosis bronchiectasis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-cystic fibrosis bronchiectasis market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Diagnosis: Computed Tomography (CT) Scan; Bronchoscopy; Chest X Ray; Lung Function; Sputum Culture Test; Blood Tests; Other Diagnosis Types2) By Treatment: Surgery; Physiotherapy; Vaccination; Airway Pharmacotherapy; Antibiotics; Other Treatments
3) By End Use: Hospitals and Clinics; Ambulatory Care Centers; Other End Uses
Subsegments:
1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT); Standard CT2) By Bronchoscopy: Flexible Bronchoscopy; Rigid Bronchoscopy
3) By Chest X-Ray: Standard Chest X-Ray; Digital Chest X-Ray
4) By Lung Function: Spirometry; Peak Flow Measurement
5) By Sputum Culture Test: Bacterial Culture; Fungal Culture; Viral Culture
6) By Blood Tests: Complete Blood Count (CBC); C-Reactive Protein (CRP); Immunoglobulin Levels
7) By Other Diagnosis Types: Sweat Test; Genetic Testing; Exhaled Nitric Oxide Test
Key Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Sanofi SA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Non-Cystic Fibrosis Bronchiectasis market report include:- Pfizer Inc.
- F Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bayer AG
- Sanofi SA
- Bristol-Myers Squibb Company
- AstraZeneca plc
- Abbott Laboratories
- Novartis AG
- GlaxoSmithKline plc (GSK)
- Boehringer Ingelheim International GmbH
- Viatris Inc
- Teva Pharmaceutical Industries Ltd
- Vertex Pharmaceuticals
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma Ltd
- Dr Reddy's Laboratories Ltd
- Chiesi Farmaceutici SpA
- Lupin Limited
- Zambon Company SpA
- Sunovion Pharmaceuticals Inc
- Insmed Incorporated
- Genentech
- Zydus Cadila
- Santhera Pharmaceuticals
- TSRL Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 3.74 Billion |
| Forecasted Market Value ( USD | $ 4.82 Billion |
| Compound Annual Growth Rate | 6.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
